Valuation: Bioventix PLC

Market Cap 88.82M 118M 104M 98.39M 167M 11.31B 170M 1.18B 453M 5.78B 443M 433M 18.53B P/E 2026 *
12.7x
P/E 2027 * -
Enterprise Value 83.93M 111M 98.12M 92.97M 158M 10.68B 160M 1.11B 428M 5.46B 418M 409M 17.51B EV / Sales 2026 *
6.71x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
8.82%
Yield 2027 * -
1 day+3.03%
1 week+9.68%
1 month-1.73%
3 months+3.03%
6 months+13.33%
Current year-10.76%
1 week 1,500
Extreme 1500
1,750
1 month 1,450
Extreme 1450
1,800
Current year 1,300
Extreme 1300
1,950
1 year 1,300
Extreme 1300
2,500
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 2003-12-22
Director of Finance/CFO 67 2020-06-30
Director TitleAgeSince
Director/Board Member 67 2010-11-24
Chairman 66 2004-10-31
Director/Board Member 67 2020-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
4/28/26 Buy

Chief Financial Officer

66 0.0013%
4/20/26 Free

Chief Executive Officer

9,967 0.1908%
4/20/26 Free

Chief Financial Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
+3.03%+9.68%-30.61%-56.02% 114M
+4.16%-0.36%+49.37%+94.17% 71.53B
-0.19%+1.32%+37.20%+83.85% 60.12B
-1.51%+2.39%+9.10%+35.15% 48.85B
-0.05%+0.37%+41.54%+36.65% 44.28B
+0.38%+7.61%+339.53%+641.55% 43.83B
+0.18%+0.26%+7.41%+103.45% 41.53B
-0.67%+0.17%+7.60%+46.37% 30.13B
+4.77%+6.16%+36.77%+22.78% 27.98B
-1.29%-3.55%-20.74%+352.04% 25.25B
Average +0.88%+2.03%+47.72%+136.00% 39.36B
Weighted average by Cap. +0.80%+1.38%+60.90%+148.49%

Financials

2026 *2027 *
Net sales 12.5M 16.6M 14.61M 13.85M 23.56M 1.59B 23.86M 166M 63.75M 813M 62.31M 60.96M 2.61B -
Net income 7.11M 9.44M 8.31M 7.88M 13.4M 905M 13.58M 94.25M 36.27M 463M 35.45M 34.68M 1.48B -
Net Debt -4.89M -6.5M -5.72M -5.42M -9.22M -623M -9.34M -64.86M -24.96M -318M -24.4M -23.87M -1.02B -
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
26-09-30 GBX 1,700.00 +3.03% 15,390
26-09-29 GBX 1,650.00 -.--% 3,619
26-09-28 GBX 1,650.00 +3.12% 8,548
26-09-25 GBX 1,600.00 +3.23% 18,536
26-09-24 GBX 1,550.00 -.--% 2,938
Trader
Investor
Global
-
Quality
ESG MSCI
CCC

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BVXP Stock